Amarin (AMRN) vs Vicore Pharma AB (VCRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Amarin is the larger company by market cap ($253.3 million vs $248.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMRN | VCRE |
|---|---|---|
| Share price | $11.99 | $8.82 |
| Market cap | $253.26M | $248.41M |
| 1-day change | -0.25% | +1.85% |
| YTD return | -13.90% | — |
| 1-year return | -37.62% | — |
| 5-year return | -88.35% | — |
| Forward P/E | 12.23 | — |
| EPS (TTM) | $-1.20 | $-2.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $20.90 | $17.80 |
| 52-week low | $11.83 | $7.88 |
| Distance from 52-week high | -42.63% | -50.45% |
| Analyst consensus | none | none |
| Avg. price target upside | +4.25% | +275.96% |
| Average volume | 66.16K | 16.24K |
| Shares outstanding | 21.12M | 28.16M |
| Employees | 80 | 46 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Amarin
AMRN stock →Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 80 employees
About Vicore Pharma AB
VCRE stock →Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension.
Health Care · Biotechnology: Pharmaceutical Preparations · 46 employees
AMRN vs VCRE FAQ
Which is bigger, Amarin or Vicore Pharma AB?
Amarin (AMRN) is larger, with a market capitalization of $253.26M compared with $248.41M for Vicore Pharma AB (VCRE).
Are Amarin and Vicore Pharma AB in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.